Text Size

Assessment of Noninvasive Methods to Identify Patients at Risk of Serious Arrhythmias After a Heart Attack

This study has been completed.
Sponsor:
Collaborators:
Canadian Institutes of Health Research (CIHR)
Heart and Stroke Foundation of Canada
Alberta Heritage Foundation for Medical Research
GE Healthcare
Cambridge Heart Inc.
Hoffmann-La Roche
Information provided by:
University of Calgary
ClinicalTrials.gov Identifier:
NCT00399503
First received: November 13, 2006
Last updated: NA
Last verified: November 2006
History: No changes posted
  Purpose

This study evaluates the usefulness of noninvasive tests of the structure of the heart and the nervous system controlling the heart. It will assess whether combining tests that evaluate heart structure with others that measure the nervous system controlling the heart will identify most patients who develop serious heart rhythm problems after a heart attack.


Condition Intervention
Myocardial Infarction
Death, Sudden, Cardiac
Death
 Procedure: Spectral T Wave Alternans
Procedure: Modified Moving Average T Wave Alternans
Procedure: Baroreceptor Sensitivity
Procedure: Heart Rate Variability
Procedure: Heart Rate Turbulence
Procedure: Deceleration Capacity
Procedure: Signal Averaged ECG

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Risk Estimation Following Infarction Noninvasive Evaluation (REFINE)

Resource links provided by NLM:

MedlinePlus related topics: Heart Attack
U.S. FDA Resources

Further study details as provided by University of Calgary:

Estimated Enrollment: 350
Study Start Date: September 2001
Estimated Study Completion Date: October 2006
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed MI <31 days, based upon elevated cardiac-specific CK (total CK-MB mass >7ng/mL or CK-MB/total CK ≥ 2.5%) or troponin-T (> 0.1 ng/ml)144) plus
  • clinical symptoms or ECG evidence of myocardial injury (ST deviation ≥ 1 mm in 2, contiguous leads or new/previously undocumented Q waves)144, &
  • left ventricular ejection fraction ≤ 0.40 within 48 hrs or ≤ 0.50 beyond 48 hrs of MI using (echocardiography, radionuclide or contrast angiography) &
  • Sinus rhythm at the time of enrollment.

Exclusion Criteria:

  • Geographic isolation or inability to return for follow-up,
  • Comorbid illness likely to cause death within 24 months,
  • Inability to complete a submaximal exercise test (e.g., urgent CABG),
  • Class I indication for a defibrillator (e.g., VF or sustained VT > 48 hours of index MI), or
  • Lack of written informed consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00399503

Locations
Canada, Alberta
Foothills Hospital
Calgary, Alberta, Canada, T2N4N1
Sponsors and Collaborators
University of Calgary
Canadian Institutes of Health Research (CIHR)
Heart and Stroke Foundation of Canada
Alberta Heritage Foundation for Medical Research
GE Healthcare
Cambridge Heart Inc.
Hoffmann-La Roche
Investigators
Principal Investigator: Derek V Exner, MD, MPH Libin Cardiovascular Institute of Alberta, University of Calgary
  More Information

No publications provided by University of Calgary

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00399503     History of Changes
Other Study ID Numbers: CIHR 73-1518, HSFA 73-1220
Study First Received: November 13, 2006
Last Updated: November 13, 2006
Health Authority: Canada: Canadian Institutes of Health Research

Keywords provided by University of Calgary:
Noninvasive assessment
Combined parameter
Holter

Additional relevant MeSH terms:
Death
Death, Sudden
Infarction
Myocardial Infarction
Death, Sudden, Cardiac
Pathologic Processes
Ischemia
 Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Heart Arrest

ClinicalTrials.gov processed this record on May 23, 2013